Defects in insulin signalling are among the most common and earliest defects that predispose an individual to the development of type 2 diabetes [1] [2] [3] . MicroRNAs have been identified as a new class of regulatory molecules that influence many biological functions, including metabolism 4, 5 . However, the direct regulation of insulin sensitivity by microRNAs in vivo has not been demonstrated. Here we show that the expression of microRNAs 103 and 107 (miR-103/ 107) is upregulated in obese mice. Silencing of miR-103/107 leads to improved glucose homeostasis and insulin sensitivity. In contrast, gain of miR-103/107 function in either liver or fat is sufficient to induce impaired glucose homeostasis. We identify caveolin-1, a critical regulator of the insulin receptor, as a direct target gene of miR-103/107. We demonstrate that caveolin-1 is upregulated upon miR-103/107 inactivation in adipocytes and that this is concomitant with stabilization of the insulin receptor, enhanced insulin signalling, decreased adipocyte size and enhanced insulin-stimulated glucose uptake. These findings demonstrate the central importance of miR-103/107 to insulin sensitivity and identify a new target for the treatment of type 2 diabetes and obesity.
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To identify microRNAs (miRNAs) that are deregulated in obesity and insulin resistance, we performed miRNA microarray analysis on the livers of two types of obese mice: ob/ob mice and diet-inducedobese (DIO) C57BL/6J mice (Supplementary Table 1a -c). The miR-103/miR-107 family was among the five most-upregulated miRNAs in the livers of both obese models, and the expression of these miRNAs was also reportedly increased in diabetic Goto-Kakizaki rats 6 . The expression levels were validated by northern blotting, demonstrating a twofold to threefold upregulation in the livers of both models (Fig. 1a) . The sequences of mature miR-103 and miR-107 differ by one nucleotide at position 21 and cannot be discriminated by northern blotting. By real-time PCR, we could distinguish miR-103 and miR-107 and show that both miRNAs are upregulated in the livers of ob/ob and DIO mice ( Supplementary Fig. 1a-d) . We also measured the expression of these miRNAs in liver biopsies from a cohort of human patients. miR-103 and miR-107 levels were similar in normal subjects and in subjects with viral hepatitis, but increased in alcoholic liver disease (ALD), non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), conditions often associated with diabetes 7 . Furthermore, there was a positive correlation between the subjects' homeostatic model assessment (HOMA) index and miR103/ 107 expression levels ( Fig. 1b and Supplementary Fig. 2a-c) , indicating an association of these miRNAs with insulin resistance.
To investigate the effect of elevated miR-103/107 expression, we generated recombinant adenovirus expressing miR-107 (ad-107/ GFP). Injection of wild-type mice with ad-107/GFP ( Supplementary  Fig. 3a , b) caused a rise in both random and fasting blood-glucose levels, and also in insulin levels (Fig. 1c, d ). It impaired glucose tolerance after an intra-peritoneal glucose injection and decreased insulin sensitivity relative to that in control ad-GFP-infected mice (Fig. 1e, f) . Hepatic overexpression of miR-107 resulted in increased glucose production during an intraperitoneal pyruvate-tolerance test (Fig. 1g) . The increase in hepatic glucose production was accompanied by augmented expression of glucose 6-phosphatase, phosphoenolpyruvate carboxykinase, pyruvate carboxylase and fructose 1, 6 biphosphatase, indicating that increased gluconeogenesis is the primary cause of the elevated glucose levels (Fig. 1h) . These data show that gainof-function of miR-107 in the liver decreases insulin sensitivity and enhances hepatic glucose production.
To study the effect of miR-103/107 silencing, we first tested whether antagomirs 8 would inhibit both miR-103 and miR-107. Northern blot analysis of miR-103 and miR-107 showed that antagomir-103 (ant-103) effectively and specifically silenced both miRNAs in liver and fat ( Supplementary Fig. 3c, d ). Markers for liver damage and inflammation were unaffected by the treatment (data not shown). Application of ant-103 did not affect blood glucose levels in chow-fed wild-type mice but it did lower plasma glucose levels in ob/ob mice when compared to mice treated with PBS or with the controls ant-124 (scrambled) or mismatchant-103 (ant-MM103) (Fig. 2a, b) . Similar effects were observed in DIO mice (Fig. 2c) . Glucose-tolerance and insulin-tolerance tests showed that there was improved glucose tolerance and insulin sensitivity in both ob/ob and DIO mice that were injected with ant-103 ( Fig. 2d-f) . A pyruvate-tolerance test revealed that de novo hepatic glucose production was reduced (Fig. 2g) and this finding was supported by a reduction in hepatic expression of glucose 6-phosphatase, pyruvate carboxylase and fructose 1, 6 -biphosphatase in ant-103-treated mice (Fig. 2h) . In addition, liver glycogen content was increased and plasma insulin levels were decreased in ant-103-treated ob/ob and DIO animals (Fig. 2i, j) . Metabolic and energy-expenditure studies carried out in metabolic cages showed that ob/ob mice lacking miR-103 expression had increased O 2 consumption and CO 2 production, as well as moderately elevated body temperature, but that their food intake was similar to control mice. Gene expression analysis in adipocytes from ant-103-treated mice revealed increased levels of b-oxidation genes (carnitine palmitoyltransferase 1a (Cpt1a), peroxisomal acyl-coenzyme A oxidase 3 (Acox3) and very long chain acyl-coenzyme A dehydrogenase (Acadvl)) but there were no changes in the lipogenic genes acetylcoenzyme A carboxylase alpha and beta (Acaca and Acacb, also known as Acc1 and Acc2) ( Supplementary Fig. 4a-d) . Two independent indicators of insulin sensitivity, the glucose infusion rate and clamp glucose turnover, were improved during hyperinsulinaemic-euglycaemic clamp studies in ant-103-treated ob/ob mice compared to PBS-injected controls. Hepatic glucose production was decreased and glucose uptake in adipose tissue was enhanced in ant-103-treated animals. In contrast, treatment with ant-103 did not improve glucose uptake in skeletal muscle (Supplementary Table 2 ). Together, these data demonstrate that silencing of miR-103/107 enhances insulin sensitivity in liver and adipose tissue.
To test the contribution of the liver to the effect on insulin sensitivity, we delivered ant-103 and control ant-MM103 specifically to the liver through liposomal formulations. Liposomal ant-103 induced the specific silencing of miR-103 in the liver, but not in fat and muscle. Silencing of miR-103/107 in the livers of ob/ob mice had no effect on a, Northern blot of liver RNA from C57BL/6J (WT), ob/ob, chow-fed or DIO mice, as indicated (n 5 3). The loading control labelled 'total RNA' is stained with ethidium bromide. b, Correlation between relative miR-103 levels (Rel. miR-103) and HOMA index in a group of humans including healthy individuals (n 5 6), chronic hepatitis B and hepatitis C virus-infected individuals (HBV, n 5 6; HCV, n 5 7), patients with alcoholic steatohepatitis (n 5 4), patients with non-alcoholic fatty liver disease (n 5 13) and patients with non-alcoholic steatohepatitis (n 5 13). c, Blood glucose levels of C57BL/6J mice injected with PBS, ad-GFP or ad-107/GFPBL/ (n 5 6). d, Plasma insulin levels of C57BL/6J mice treated as in c, after a 12 h fast followed by re-feeding. e-g, Glucosetolerance test (e), insulin-tolerance test (f) and pyruvate-tolerance test (g) in mice injected with ad-GFP or ad-107/GFP. h, Relative mRNA expression of genes encoding glucose 6-phosphatase (G6Pc), phosphoenol-pyruvate carboxykinase (Pepck), pyruvate carboxylase (PC) and fructose 1,6-biphosphatase (FBPase) from livers of mice as in e-g. Expression is normalized to the 36B4 gene, encoding the acidic ribosomal phosphoprotein P0 (RPLP0) (n 5 5). Means 6 s.d. are shown for all panels. *, P , 0.05; **, P , 0.01; ***, P , 0.001.
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blood glucose levels, plasma insulin levels or glucose-tolerance, insulin-tolerance and pyruvate-tolerance tests ( Supplementary Fig.  5a -f), indicating that silencing of miR-103/107 in the liver is not sufficient to reverse insulin resistance in obese mice. Because the expression of miR-103 is about eightfold higher in adipose tissue than in liver and muscle, we examined the effect of miR-103/107 silencing in adipose tissue. Obese (ob/ob) mice showed a slight reduction in body weight when miR-103/107 were systemically silenced ( Supplementary  Fig. 6a ). In contrast, specific manipulation of hepatic miR-103/107 expression using liposomal ant-103 or Ad-107/GFP did not affect body weight when compared to that of control-treated mice (data not shown). We therefore used computer tomography to investigate the fat distribution of DIO and ob/ob animals after miR-103 silencing. Both DIO and ob/ob mice treated with ant-103 showed reduced levels of total fat, owing to a decrease in both subcutaneous and visceral adipose tissue (Fig. 3a, b) . Furthermore, organ measurements revealed a decrease in inguinal fat-pad weights in the ant-103-treated group but no weight differences in other organs ( Supplementary Fig. 6b ). To investigate whether this reduction was due to lower cell numbers or smaller adipocytes, we quantified the mean size of adipocytes from fat tissue sections using automated image-analysis software. Ant-103-treated DIO and ob/ob animals had smaller adipocytes than ant-MM103-injected controls (Fig. 3c, d ), owing to an increased number of small adipocytes and a decreased number of large ones (Supplementary Fig. 6c-f) . A comparison between the decrease in fat-pad size, measured by computer tomography, and the average decrease in adipocyte size showed that ant-103-treated mice had approximately 10-20% more adipocytes than ant-MM103-treated controls. Because miR-103 has been implicated in adipocyte differentiation [9] [10] [11] [12] [13] , we explored whether the increase in adipocyte number in miR-103-depleted mice could be attributed to changes in pre-adipocyte differentiation. We induced adipocyte differentiation of isolated stromal-vascular cells from both visceral and subcutaneous fat in the presence of either ant-103 or ant-MM103. Quantification of mature adipocyte numbers by high-content imaging after 8 d in culture demonstrated a 2-fold and 2.5-fold increase in the number of differentiated adipocytes in the ant-103-treated stromal-vascular cells derived from visceral and subcutaneous fat, respectively. This indicates that the absence of miR-103 enhances adipocyte differentiation in a cell-autonomous fashion. Conversely, overexpression of miR-107 decreased the number of differentiated adipocytes (Fig. 3e) . The negative effect of miR-103 on pre-adipocyte differentiation was further corroborated by gene expression analysis of an early marker of adipocyte differentiation, CCAAT/enhancer binding protein (C/ EBP)-b (Cebpb), and of two late markers of adipocyte differentiation, peroxisome proliferator activated receptor-c (Pparg) and adipocyte fatty acid binding protein 4 (Fabp4) (Fig. 3f-h) .
To test whether fat-specific overexpression of miR-107 affects insulin sensitivity, we injected either ad-107/GFP or ad-GFP into the inguinal fat pads of wild-type mice. The relative size of the inguinal fat deposit was 20.7% 6 6.3% of total body fat, as determined by computer tomography. Expression of miR-107 was increased by about 1.6-fold and was restricted to the fat pad. Levels of blood glucose and insulin in mice injected with ad-107/GFP were increased and glucosetolerance and insulin-tolerance tests showed decreased glucose tolerance and insulin sensitivity, respectively, supported by an increase in the HOMA index. Furthermore, adipocyte size was increased in the fat pads injected with ad-miR-107, compared to the ad-GFP controls (Supplementary Fig. 7a-g ). These data show that overexpression of miR-107 in the fat is sufficient to induce insulin resistance and glucose intolerance.
Smaller adipocytes are associated with increased insulin sensitivity in human and rodent models 14 . To explore whether insulin-stimulated glucose uptake in adipocytes was affected by miR-103 silencing, we isolated primary adipocytes from ob/ob mice injected with either ant-103 or ant-MM103 and measured insulin-stimulated D- 14 C-glucose uptake in vitro. Basal and insulin-stimulated glucose uptake was increased in adipocytes from both subcutaneous and visceral fat of ant-103-injected animals (Fig. 3i) . Furthermore, adiponectin levels, which correlate positively with insulin sensitivity 15 , were increased in ant-103-injected ob/ob mice (Fig. 3j) . Together, these data show that silencing of miR-103/107 increases insulin sensitivity in adipocytes.
To address the possible mechanism by which miR-103 and miR-107 regulate insulin sensitivity, we performed genome-wide expression analysis using Affymetrix microarrays, comparing livers from C57BL/6J mice infected with ad-107/GFP or ad-GFP. In animals 5 7) , and in ad-GFP-injected or ad-107/GFP-injected C57BL/6J mice (right, n 5 9). Means 6 s.d. are shown for all panels. *, P , 0.05; **, P , 0.01; ***, P , 0.001.
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infected with ad-107/GFP, mRNAs carrying a seed match to miR-107 in the 39 untranslated region (39 UTR) were downregulated when compared to transcripts that lacked a miR-107 seed. The data were confirmed by real-time PCR for a subset of miR-107 target genes (Fig. 4a) . Out of over 3,000 genes with a 6-mer seed match in the 39 UTR, the predicted top 100 targets of miR-107/103 were enriched in membrane-related genes and metabolism genes ( Supplementary  Fig. 8a, b) . The gene encoding caveolin-1 (Cav1), a key component of caveolae and a mediator of insulin signalling, was among the miR-103/107 seed-containing genes that were downregulated after overexpression of miR-107 in the liver, and upregulated after its silencing ( Fig. 4a and Supplementary Fig. 8c) . Notably, miR-103 silencing in the fat resulted in an approximately 3.5-fold upregulation of Cav1 mRNA levels (Fig. 4b) . Murine Cav1 (mCav1) contains three miR-103 sites, whereas human CAV1 (hCAV1) has two seed motifs in the 39 UTR ( Supplementary Fig. 8d, e) . Measurements of luciferase activity in HEK 293 cells transfected with reporter plasmids containing the 39 UTRs of mCav1or hCAV1 showed reduced expression of these constructs in the presence of miR-103 (Fig. 4c) . By mutating the conserved seed, we could fully reverse the miR-103-induced decrease in luciferase activity in both mCav1 and hCAV1 constructs (Fig. 4c) . Overexpression of miR-103 also led to an approximately twofold decrease in endogenous Cav1 levels in HEK 293 cells compared to controls (Fig. 4d) . Conversely, ant-103, but not ant-scrambled or PBS controls, increased Cav1 levels in HEK 293 cells (Fig. 4e) .
Taken together, these data demonstrate that Cav1 is a direct target of miR-103 in both mouse and human cells.
Cav1 is the principal protein of caveolae 16 , distinct lipid-and cholesterol-enriched vascular invaginations at the plasma membrane. Cav1 activates insulin signalling, probably by stabilizing caveolae and their associated insulin receptors 17 . Peptides corresponding to the scaffolding domain of Cav1 and Cav3 potently stimulate insulin-receptorkinase activity 18 . Furthermore, overexpression of Cav3 augments insulin-stimulated phosphorylation of insulin receptor substrate 1 (ref. 18 ) and increases hepatic insulin-receptor phosphorylation in response to insulin stimulation, thereby improving the overall glucose metabolism of diabetic mice 19 . Cav1-null mice are phenotypically normal on a chow diet but develop insulin resistance on a high-fat diet owing to decreased insulin-receptor expression and diminished insulin-receptor signalling in adipose tissue 20 . We investigated whether insulin signalling correlated with miR-103/107-mediated changes in Cav1 expression. In the fat and liver of ob/ob mice, silencing of miR-103/107 resulted in increased Cav1 levels, whereas no expression of this protein could be detected in skeletal muscle (Fig. 4f-h ). The expression of insulin receptor b-subunit (IRb) in adipocytes was increased and insulin-stimulated levels of phosphorylated Akt1 and IRb (pAkt1 and pIRb) were augmented in the fat and liver of ant-103-treated mice (Fig. 4f, g ). In contrast, insulin signalling was not enhanced in the skeletal muscle of ant-103-treated mice (Fig. 4h) . In addition, wild-type mice in which ad-miR-107 was injected into the inguinal fat pad 0 0.5 
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showed a reduction in Cav1 expression and decreased IRb and pAkt1 levels (Fig. 4i) . We also studied insulin signalling in the livers of mice with miR-107 overexpression. Cav1 and pAkt1 levels were diminished in the livers of wild-type mice infected with ad-miR-107, with no changes observed in IRb protein levels (Fig. 4j) . This result is in agreement with our findings showing that overexpression of miR-107 can induce hepatic insulin resistance, and with data from Cav1-null mice, which maintain normal IRb levels in the liver but show reduced IRb and pAkt1 levels in fat [19] [20] [21] . Finally, to investigate whether modulation of Cav1 expression by miR-107 is important for the observed phenotypes, we overexpressed or silenced miR-103/107 in DIO Cav1-null mice. Whereas hepatic overexpression of miR-107 in wild-type mice led to impaired glucose tolerance, no significant effects on plasma glucose, glucose-tolerance, insulin-tolerance or pyruvate-tolerance tests were measured when Cav1-null mice were injected with ad-107/GFP and compared to ad-GFP-treated Cav1-null animals ( Supplementary Fig. 9a-d) . Furthermore, no molecular changes in insulin signalling events were detected in the two groups (Fig. 4j) . Administration of ant-103 to DIO Cav1-null mice also did not affect glucose tolerance, insulin sensitivity or phosphorylation of insulin receptor and Akt1 upon insulin stimulation ( Fig. 4k and Supplementary Fig. 9e-h ). However, expression of lipolytic genes in the adipose tissue of Cav1-null mice was still responsive to treatment with ant-103, compared to ant-MM103 ( Supplementary Fig. 9i ), indicating that miR-103/107 also mediate some Cav1-independent metabolic effects.
Our findings show that miR-103 and miR-107 are negative regulators of insulin sensitivity. Their increased hepatic expression in rodents and humans with insulin resistance and hepatic steatosis indicates that they might contribute to the aetiology of diabetes. We also show that global miR-103/107 silencing causes increased insulin signalling in both liver and adipose tissue, although silencing of hepatic miR-103/107 expression in overt obese and insulin-resistant states is insufficient to reverse the metabolic abnormalities. This indicates that silencing of miR-103 in adipocytes is the dominant contributor to enhanced insulin sensitivity. One mechanism by which these miRNAs regulate insulin sensitivity is by targeting Cav1, thereby diminishing the number of insulin receptors in caveolae-enriched plasma membrane microdomains and reducing downstream insulin signaling. It is likely that Cav1 also mediates other effects that contribute to the phenotype because this protein has many functions in growth-factor signalling, endocytotic pathways and lipid regulation 22 . Our finding that silencing miR-103/107 in obese animals improves glucose homeostasis implicates these miRNAs as novel therapeutic targets for the treatment of diabetes.
METHODS SUMMARY
Animals. All mice were males and were maintained on a C57BL/6J background, on a 12-h light/dark cycle in a pathogen-free animal facility. Antagomirs at doses of 15 mg kg 21 in 0.2 ml total volume with PBS per injection were administered on two consecutive days through the tail vein of wild-type or ob/ob mice at between 6 and 8 weeks of age, or to 12-week-old DIO mice fed on a diet containing 60% fat (Pvolimi Kliba AG) for 8 weeks. Mice were injected with adenoviruses through the tail vein at 1 3 10 9 plaque-forming units in 0.2 ml PBS. Injection of ad-107/GFP and antagomirs did not effect food consumption compared to that of controltreated animals. Mice were killed 10 d after the adenovirus injection. All animal studies were approved by the Kantonale Veterinäramt Zürich. Lipid nanoparticle formulations. Liver-targeting lipid nanoparticle formulations of antagomirs were prepared using the novel ionizable lipid DLin-KC2-DMA (ref. 22) . Lipid nanoparticles were composed of DLin-KC2-DMA, distearoyl phosphatidylcholine, cholesterol and mPEG2000-DMG, used at the molar ratio 50:10:38.5:1.5. Antagomirs were formulated in lipid nanoparticles at a total lipidto-antagomir weight ratio of approximately 11:1. Generation of recombinant adenovirus. Ad-107/GFP was generated by inserting the PCR-amplified miRNA precursor sequence generated with primers 59-AATACCCGCATGGAAGCAGGCTAA-39 and 59-AACATGTCTCAAGGA GAGGACGGT-39 into a GFP-expressing shuttle vector, Ad5CMV K-NpA. Ad-GFP (ViraQuest) was used as a control. Statistical analysis. Unless otherwise specified, all bars show mean 6 s.d. Significance was calculated using student's t-test (*, P , 0.05; **, P , 0.01; ***, P , 0.001).
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
